Work

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality

Year: 2017

Type: article

Study design: Observational Study

Source: Bone Marrow Transplantation

DOI: 10.1038/bmt.2017.73

Authors: R M Saliba, S Sarantopoulos, C L Kitko, A Pawarode, S C Goldstein, J Magenau, A M Alousi, T Churay, H Justman, S Paczesny, P Reddy, D R Couriel

Institutions: The University of Texas MD Anderson Cancer Center, Duke University, Duke Cancer Institute, Vanderbilt University Medical Center, University of Michigan, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Huntsman Cancer Institute, University of Utah Hospital

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute

Awards: UNC Oncology K12, Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease, G4720334866, Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD

OpenAlex ID: W2612469248

FWCI: 2.735

Cites: 38

Cited by: 26

Related to: 10